No Prescription |
 |
 | ||
|
LOMIBACT Maxaquin |
|
| ||
No Prescription » Prescription Drugs 10 » LOMIBACT Maxaquin Lomefloxacin is broad spectrum antibiotics used in the treatment of Acute bacterial exacerbation of chronic bronchitis complicated and uncomplicated urinary tract infections. Dosage 400mg PO daily for 10 days. Buy LOMIBACT Maxaquin and other Prescription Drugs 10 products online at Medstore. Buy Online at Medstore - Click Here!
About LOMIBACT Maxaquin: Product Type: Prescription Drugs 10 LOMIBACT ( Maxaquin GENERIC Lomefloxacin ) LOMIBACT (Maxaquin GENERIC Lomefloxacin) Maxaquin GENERIC Lomefloxacin 3mg/5ml Maxaquin GENERIC Lomefloxacin LOMIBACT
View more Prescription Drugs 10 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
